Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVES: The aim of the study was to investigate whether lamivudine (3TC) or emtricitabine (FTC) use following detection of M184V/I is associated with better virological outcomes. METHODS: We identified people with viruses harbouring the M184V/I mutation in UK multicentre data sets who had treatment change/initiation within 1 year. We analysed outcomes of viral suppression (

Original publication

DOI

10.1111/hiv.12829

Type

Journal article

Journal

HIV Med

Publication Date

05/2020

Volume

21

Pages

309 - 321

Keywords

HIV, M184I, M184V, emtricitabine, lamivudine